#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13924	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2244	606.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1475	1475	C	901	C,T	780,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26452	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3799	683.3	0	.	n	.	0	T695C	SNP	695	695	T	1217	1217	C	1014	C	912	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26452	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3799	683.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1859	1859	A	762	A	696	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26452	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3799	683.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2493	2493	C	753	C	640	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26452	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3799	683.3	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2567	2567	G	839	G,A	716,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26452	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3799	683.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3119	3119	C	790	C	672	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	898	folP	852	852	100.0	folP.l15.c4.ctg.1	1801	48.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1157	1159	AGC	99;99;100	A;G;C	87;86;87	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2484	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3488	69.1	1	SNP	p	S91F	0	.	.	271	273	TCC	672	674	TCC	88;89;88	T;C;C	80;81;80	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2484	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3488	69.1	1	SNP	p	D95N	0	.	.	283	285	GAC	684	686	GAC	91;93;93	G;A;C	84;86;86	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2484	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3488	69.1	1	SNP	p	D95G	0	.	.	283	285	GAC	684	686	GAC	91;93;93	G;A;C	84;86;86	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	674	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1365	47.7	1	SNP	p	G45D	1	.	.	133	135	GAC	518	520	GAC	75;77;77	G;A;C	64;65;66	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	544	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	959	52.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2274	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	75.3	1	SNP	p	D86N	0	.	.	256	258	GAC	593	595	GAC	109;109;109	G;A;C	106;100;105	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2274	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	75.3	1	SNP	p	S87W	0	.	.	259	261	AGT	596	598	AGT	104;107;108	A;G;T	101;105;104	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2274	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	75.3	1	SNP	p	S87R	0	.	.	259	261	AGT	596	598	AGT	104;107;108	A;G;T	101;105;104	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2274	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	75.3	1	SNP	p	S87I	0	.	.	259	261	AGT	596	598	AGT	104;107;108	A;G;T	101;105;104	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2274	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2903	75.3	1	SNP	p	S88P	0	.	.	262	264	TCC	599	601	TCC	106;106;105	T;C;C	101;103;102	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1934	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2858	65.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1524	1526	GGC	51;51;51	G;G;C	45;45;45	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1186	1188	GCA	148;148;146	G;C;A	129;129;127	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1189	1191	ATC	141;141;141	A;T;C	123;123;123	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1201	1203	GTG	140;142;140	G;T;G	123;122;124	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1201	1203	GTG	140;142;140	G;T;G	123;122;124	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1705	1707	ACC	83;83;82	A;C;C	76;77;76	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1759	1761	GCG	65;63;65	G;C;G	63;59;61	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1759	1761	GCG	65;63;65	G;C;G	63;59;61	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1882	1884	GGC	68;66;66	G;G;C	60;59;59	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1891	1893	GGC	51;51;49	G;G;C	46;46;44	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2346	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2195	103.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1909	1911	CCG	37;37;39	C;C;G	35;36;36	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	4492	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3004	144.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1471	1473	CTG	72;71;72	C;T;G	68;69;70	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1164	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2030	55.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	595	595	C	50	C	44	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	A26V	NONSYN	76	78	GCC	224	226	GTC	106;106;106	G;T;C	94;94;94	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	290	292	GGA	124;124;128	G;G;A	101;101;103	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	407	409	GCT	91;91;91	G;C;T	84;84;84	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	413	415	AGC	88;87;85	A;G;C	81;81;79	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	505	506	CG	90;89	C;G	77;77	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	508	510	CAG	90;90;89	C;A;G	79;78;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	512	514	AAA	95;100;102	A;A;A	80;85;87	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	A125T	NONSYN	373	375	GCT	521	523	ACT	103;104;101	A,G;C;T	90,1;93;87	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	N134S	NONSYN	400	402	AAT	548	550	AGT	98;98;102	A;G;T	85;86;86	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	E137K	NONSYN	409	411	GAA	557	559	AAA	98;98;99	A;A;A	89;89;90	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	575	577	GAA	101;103;105	G;A;A	89;91;93	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	599	601	GCA	105;106;106	G;C;A	93;93;93	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	707	709	CAA	175;175;175	C;A;A	150;151;151	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	N189S	NONSYN	565	567	AAC	713	715	AGC	168;168;167	A;G;C	142;142;143	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	M209I	NONSYN	625	627	ATG	773	775	ATC	155;155;157	A;T;C	132;131;131	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	0	.	p	.	0	E210fs	FSHIFT	628	628	G	776	776	G	156	G	131	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	1	SNP	p	G120K	1	.	.	358	360	AAG	505	507	CGG	90;89;89	C;G;G	77;77;78	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	1	SNP	p	A121D	1	.	.	361	363	GAC	508	511	CGC	90;89;95	C;G;C	79;78;79	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1434	porB1b	1041	1041	96.56	porB1b.l15.c30.ctg.1	1340	103.0	1	SNP	p	D121N	0	.	.	361	363	GAC	508	511	CGC	90;89;95	C;G;C	79;78;79	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	6130	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4937	121.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1870	1872	AAT	148;150;153	A;A;T	132;133;136	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	532	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1187	43.8	1	SNP	p	V57M	1	.	.	169	171	ATG	605	607	ATG	98;102;105	A;T;G	91;95;96	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
